Thus, four groups were obtained, including the normal AD biomarkers groups(A-(TN)-), only Aβ-pathology groups (A+(TN)-), both Aβ-pathology and its downstream processes of tau pathology or neurodegeneration A+(TN)+, and suspected non-AD pathology groups (A-(TN)+). The gene discussed is MAPT; the disease is Alzheimer disease.